Clinical trial · no report yet · Phase 2
NCT05912244
A Study of IO102/IO103, Nivolumab, and Relatlimab in People With Melanoma
- NCT05912244 ↗
- Active, not recruiting
- Memorial Sloan Kettering Cancer Center
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| YouTube | 3 | |
| Podcasts | 2 | |
| X threads | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase II Study of IO102/IO103 and Nivolumab-relatlimab Fixed Dose Combination in Untreated, Unresectable Stage III/IV Melanoma
- Phase
- Phase 2
- Status
- Active, not recruiting
- Conditions
- Melanoma
- Interventions
- IO102/IO103; Nivolumab-Relatlimab
- Arms
- IO102/IO103, Nivolumab, and Relatlimab · Experimental
- Enrollment
- 43
- Primary outcomes
- Overall Response Rate (ORR)
- Sponsor
- Memorial Sloan Kettering Cancer Center with IO Biotech
- Start
- Jun 9, 2023
- Primary completion
- Jun 9, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT05912244 · updated Jun 1, 2026
Publications
linked from the registry- Kjeldsen JW, Lorentzen CL, Martinenaite E, Ellebaek E, Donia M, Holmstroem RB, Klausen TW, Madsen CO, Ahmed SM, Weis-Banke SE, Holmstrom MO, Hendel HW, Ehrnrooth E, Zocca MB, Pedersen AW, Andersen MH, Svane IM. A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma. Nat Med. 2021 Dec;27(12):2212-2223. doi: 10.1038/s41591-021-01544-x. Epub 2021 Dec 9. PubMed 34887574
- Lorentzen CL, Kjeldsen JW, Ehrnrooth E, Andersen MH, Marie Svane I. Long-term follow-up of anti-PD-1 naive patients with metastatic melanoma treated with IDO/PD-L1 targeting peptide vaccine and nivolumab. J Immunother Cancer. 2023 May;11(5):e006755. doi: 10.1136/jitc-2023-006755. PubMed 37217243